Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
NVDA$184.33-15.96(-7.97%)Historically Bullish Signal Emerges for Nvidia Stock2:37:37 PM ETCOP$137.30+0.42(+0.31%)UPDATE 4-ConocoPhillips boosts dividend after beating estimates on higher oil prices2:33:40 PM ETMCD$276.81-3.42(-1.22%)McDonald's plans new value menu offerings next year to boost sluggish sales2:33:15 PM ETTSLA$344.39-40.79(-10.59%)The ‘Musk selloff' deepens as Tesla and SpaceX combine for $450 billion two-day wipeout2:29:00 PM ETPLTR$156.34-15.40(-8.97%)Prediction: These Will Be Nvidia's and Palantir's Stock Prices by 2027 (Hint: Only 1 Is a Buy)2:26:00 PM ETCOP$137.30+0.42(+0.31%)BRIEF-Conocophillips Says Q4 Forecast Incorporates Uncertainty Around Qatar Production Levels2:21:59 PM ETTSLA$344.39-40.79(-10.59%)SpaceX, Tesla extend losses as midterm results cloud data center, merger outlook2:18:16 PM ETTSLA$344.39-40.79(-10.59%)If You Invested $1,000 in Tesla at Its 2010 IPO, Here's What You'd Have Today2:17:42 PM ETNVDA$184.33-15.96(-7.97%)Nvidia stock plunges 8% as AI spending fears and financing risks mount2:13:33 PM ETMETA$606.73-22.94(-3.64%)Meta's warns that election backlash against data centers could make AI expansion harder2:12:39 PM ETGS$872.61-55.67(-6.00%)UPDATE 1-Goldman Sachs promotes 109 bankers to partner ranks but omits demographic data2:11:01 PM ETGOOG$283.80-3.66(-1.27%)What Should Alphabet Inc. Investors Know After 7.13% Stock Drop? The Law Offices of Frank R.2:10:00 PM ETTMUS$159.50+0.39(+0.25%)Sorry to Wake You, But T-Mobile and Bryan Cranston Have a Change in Plans2:06:02 PM ETAMD$419.85-68.84(-14.09%)Some of the Year's Hottest AI ETFs Are in Big Trouble Today2:03:23 PM ETMGHL$2.200.00(0.00%)Cisco Falls 7% on Morgan Stanley Downgrade; Ciena Plunges 15%, Arista Networks Tumbles 10%2:03:05 PM ETBRK-A$859,951.40-8,663.60(-1.00%)Pilot Celebrates 2026 Road Warrior Champion with Customized Kenworth W990 Truck and $50,000 Cash Prize2:02:00 PM ETPLTR$156.34-15.40(-8.97%)Why Is Palantir Stock Falling, and is it a Buying Opportunity?2:00:02 PM ETNVDA$184.33-15.96(-7.97%)As Nvidia's stock heads for a bear market, bargain hunters see a golden buying opportunity1:59:00 PM ETPLTR$156.34-15.40(-8.97%)Palantir Just Had Its Best Growth Quarter Ever. Why Are Investors Selling?1:57:22 PM ETACCS$3.49-0.09(-2.51%)The Mortgage Office Launches AI Portfolio Tools to Help Private Lenders Spot Risk Earlier and Get More from Their Data1:55:00 PM ETMETA$606.73-22.94(-3.64%)BRIEF-Meta Rolls Out Voice And Expressive Avatars In Muse App1:54:43 PM ETAMZN$260.90-5.29(-1.99%)UPDATE 1-Anthropic's models improving nearly twice as fast with help from AI, study finds1:53:21 PM ETAAPL$344.68-4.88(-1.40%)Apple Taps Bond Market for $7B as Tech Sells Off1:49:34 PM ETTSLA$344.39-40.79(-10.59%)Tesla, SpaceX Slide as Investors Price in Political Risk1:48:27 PM ET

CGTX · NASDAQ

Cognition Therapeutics, Inc.

$0.64 -0.04 (-5.88%)

Company overview

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$60.9M
Employees
25
Headquarters
Purchase, NY
Website
cogrx.com
CEO
Lisa Ricciardi
Listed
October 8, 2021
P/E
-2.44
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$129,000
Operating income
-$42.8M
EBITDA
-$23.6M
Net income
-$19.6M
EPS
-$0.26
Total assets
$36.1M
Total debt
$465,000
Earnings yield
-40.94%

Price chart

0.600.901.201.501.80
CGTX 1D NASDAQ O0.72H0.73L0.68C0.68-0.02 (-2.32%)Vol421.18K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
CGTXCognition Therapeutics, Inc. Stock news Cognition Therapeutics Q3 Earnings Call Highlights MarketBeat
CGTXCognition Therapeutics, Inc. Stock news Cognition Therapeutics Q3 net loss narrows on higher grant income Reuters
CGTXCognition Therapeutics, Inc. Press release Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update GlobeNewswire
CGTXCognition Therapeutics, Inc. Press release Cognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026 GlobeNewswire
CGTXCognition Therapeutics, Inc. Press release Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies GlobeNewswire
CGTXCognition Therapeutics, Inc. Press release Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045 GlobeNewswire
CGTXCognition Therapeutics, Inc. Press release Cognition Therapeutics Schedules a Type C Meeting with FDA GlobeNewswire
CGTXCognition Therapeutics, Inc. Press release Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference GlobeNewswire
CGTXCognition Therapeutics, Inc. Stock news Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates Zacks Investment Research
CGTXCognition Therapeutics, Inc. Press release Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update GlobeNewswire
CGTXCognition Therapeutics, Inc. Stock news Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit GlobeNewswire
CGTXCognition Therapeutics, Inc. Press release Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit GlobeNewswire
CGTXCognition Therapeutics, Inc. Press release Cognition Therapeutics Participating in Upcoming Investor Conferences GlobeNewswire
CGTXCognition Therapeutics, Inc. Press release Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis GlobeNewswire
CGTXCognition Therapeutics, Inc. Press release Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies GlobeNewswire
CGTXCognition Therapeutics, Inc. Press release Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update GlobeNewswire
CGTXCognition Therapeutics, Inc. Stock news Cognition Therapeutics (NASDAQ:CGTX) CEO Lisa Ricciardi Acquires 9,175 Shares of Stock Defense World
CGTXCognition Therapeutics, Inc. Stock news Cognition Therapeutics (NASDAQ:CGTX) CFO John Brendan Doyle Buys 10,000 Shares Defense World
CGTXCognition Therapeutics, Inc. Stock news Cognition Therapeutics Targets Faster DLB Psychosis Path as Zervimesine Nears Late-Stage Plans Defense World
CGTXCognition Therapeutics, Inc. Press release Cognition Therapeutics to Present at Needham Virtual Healthcare Conference GlobeNewswire
See more
FAQ

Questions about Cognition Therapeutics, Inc.

What does Cognition Therapeutics, Inc. do?
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc.
What is CGTX's market cap?
Cognition Therapeutics, Inc. (CGTX) is a listed stock with a live quote. The latest market cap on this page is $60.9M.
Where is Cognition Therapeutics, Inc. headquartered?
Cognition Therapeutics, Inc. is headquartered in Purchase, NY.
How do I get CGTX news from the API?
Call GET /v1/news?tickers=CGTX. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does CGTX news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for CGTX, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the CGTX price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs